The AKT1 p.E17K mutation accounts for 10% of meningiomas and induces the constitutive activation of downstream oncogenic cellular effects by localizing from the cytoplasm to the plasma membrane [107,111,127]. This evidence concerns the gene AKT1 and meningioma.